Focus on FAPI Newsletter – Q2 2023

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI community,

This quarter, the FAPI team celebrated […]

2025-12-03T20:03:58+00:0012, Jun 2023|Newsletter|

SOFIE partners with BAMF Health, diversifying sites for Phase II [68Ga]FAPI-46 study

SOFIE has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan, as […]

2025-10-15T16:42:11+00:006, Jun 2023|News|

First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial

Dulles, VA –May 12, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2025-10-15T16:42:14+00:0012, May 2023|News|

FAPI Theragnostics

Presented by: Prof. Dr. Frederik L. Giesel, MD, MBA; Chair of Nuclear Medicine, Department of […]

2025-11-03T16:08:50+00:0031, Mar 2023|Presentations|

Fibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology, Fibrotic Disease, and Cardiovascular Disease

Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
Informa Connect: Radiopharmaceuticals and Imaging Digital Conference
March […]

2025-11-04T00:28:35+00:0014, Mar 2023|Presentations|

Focus on FAPI Newsletter – Q4 2023

A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI community,

We would like to wish you […]

2025-12-03T20:03:36+00:005, Feb 2023|Newsletter|

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

Yuriko Mori 1Katharina Dendl 1Jens […]

2025-10-13T13:38:53+00:005, Feb 2023|Publications|

Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls

Tristan T Demmert 1Ines Maric 1

2025-10-15T16:40:44+00:005, Feb 2023|Publications|

SOFIE and Mayo Clinic collaborate to secure $3M NIH grant for FAPI clinical trial

The National Cancer Institute (NCI) has awarded Mayo Clinic (Rochester), in partnership with SOFIE, a […]

2025-10-13T13:39:06+00:0031, Jan 2023|News|

IND granted for FAP targeting therapeutic in SOFIE partnership

Dulles, VA – January 17, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]

2025-10-15T16:42:14+00:0017, Jan 2023|News|
Go to Top